DISCOVER: Renal Parameters and BMD Improved With FTC/TAF vs FTC/TDF for HIV PrEP at Wk 48

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Among cis-MSM and transgender women at high risk of HIV infection, initiation of daily oral FTC/TAF for PrEP associated with significantly better BMD, eGFR, and renal tubular function, as measured by urine RBP:Cr and β2M:Cr.
Format: Microsoft PowerPoint (.ppt)
File Size: 383 KB
Released: November 19, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Understand medical, social, and emotional challenges faced by older PWH, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Melanie Reese
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Marc Thompson
Released: August 9, 2022

HIV self-testing and 6-month PrEP dispensing simplified PrEP delivery with no reduction in HIV testing or PrEP adherence, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Efficacy of doxycycline PEP for prevention of STIs in MSM and TGW in the DoxyPEP study, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 4, 2022

HPTN 084 updated safety and efficacy data on long-acting cabotegravir for HIV PrEP in cisgender women, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings